Among these, the existence of a tumor-specific T cell response is supported by our findings of pre-existing, expanded CD8+ T cell clones in responders, and the maintenance of these expanded CD8+ T cell clones characterizes response to nivolumab. The gene discussed is CD8A; the disease is neoplasm.